Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mary L. Zupanc is active.

Publication


Featured researches published by Mary L. Zupanc.


Epilepsy Research | 2006

Felbamate: Consensus of current clinical experience

John M. Pellock; Edward Faught; Ilo E. Leppik; Shlomo Shinnar; Mary L. Zupanc

An expert panel convened to evaluate data and review current clinical practices regarding the novel antiepileptic drug (AED) felbamate. Felbamate has demonstrated efficacy against a variety of refractory seizures types, including seizures associated with Lennox-Gastaut syndrome, but postmarketing experience revealed serious idiosyncratic adverse effects that were not observed during clinical trials. Although felbamate is not indicated as first-line antiepileptic therapy, its utility in treating seizures that are refractory to other AEDs is undisputed, as shown by the number of patients who continue to use it. New exposures to felbamate number approximately 3200-4200 patients annually, and it is estimated that over the past 10 years, approximately 35,000 new starts have occurred. Recommendations by the American Academy of Neurology and a review of felbamate literature were evaluated in conjunction with the clinical experience of the expert panel to determine current medical opinion and practice regarding felbamate. The past 10 years of clinical experience have demonstrated that when used in accordance with existing recommendations and close clinical monitoring, felbamate is an effective treatment for some patients with seizures refractory to other AEDs. This review of clinical data and discussion of the current understanding of the risk:benefit of felbamate therapy supports its use as an important therapeutic option for some patients with refractory epilepsy.


Epilepsia | 2009

Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy

James W. Wheless; Lionel Carmant; Martina Bebin; Joan A. Conry; Catherine Chiron; Roy D. Elterman; Michael Frost; Juliann M. Paolicchi; W. Donald Shields; Elizabeth A. Thiele; Mary L. Zupanc; Stephen D. Collins

Purpose:  Vigabatrin used to treat infantile spasms (IS) has been associated with transient magnetic resonance imaging (MRI) abnormalities. We carried out a retrospective review to better characterize the frequency of those abnormalities in IS and in children and adults treated with vigabatrin for refractory complex partial seizures (CPS).


Pediatric Neurology | 2010

Epilepsy Surgery Outcomes: Quality of Life and Seizure Control

Mary L. Zupanc; Elliane J. dos Santos Rubio; Rhonda Roell Werner; Michael J. Schwabe; Wade M. Mueller; Sean M. Lew; Charles J. Marcuccilli; Sunila E. O'Connor; Maria S. Chico; Kathy A. Eggener; Kurt E. Hecox

A consecutive, retrospective analysis of seizure control and quality of life was performed among 83 pediatric patients undergoing epilepsy surgery at Childrens Hospital of Wisconsin. Seizure outcomes were generally favorable, with 68.7% class I outcomes; class II, 12%; and class III, 19.3%. Seizure freedom was highest among temporal lobectomies (84.2%) and hemispherectomies (76.2%). Outcomes among hemispherectomies were substantially superior to those of multilobar resections. Cortical dysplasia was associated with lower seizure freedom, at 57.5%. Among age groups, seizure-free outcomes in infants were lowest, at 50%. The lower infant seizure-free rate was likely attributable to frequency of multilobar resections and type of pathology (cortical dysplasia). Quality-of-life measures generally paralleled seizure outcomes. These results indicate that epilepsy surgery in children with intractable epilepsy can result in significant improvements in seizure control, quality of life, and development. Anticipated type of surgery, presumed location of epileptogenic site, absence of a defined lesion on magnetic resonance imaging scan of the brain, and patients age should not prevent surgical evaluations of children with intractable epilepsy.


The Cerebellum | 2004

Progressive myoclonic epilepsy

Mary L. Zupanc; Benjamin Legros

Progressive myoclonic epilepsies (PMEs) are a group of rare disorders characterized by the occurrence of seizures, myoclonus, and progressive neurological dysfunction. This article discusses epidemiology, genetics, pathology, clinical manifestations, EEG characteristics, methods of diagnosis and treatment of the most common causes of PME, including Unverricht-Lundborg Disease (Baltic Myoclonus), MERRF, neuronal ceroid lipofuscinosis, dentatorubropallidoluysan atrophy, Gaucher disease, Lafora disease, and sialidosis. The aim of this paper is to provide clinicians with useful clinical information in order to facilitate the diagnosis and treatment of these rare diseases.


Journal of Child Neurology | 2009

Clinical Evaluation and Diagnosis of Severe Epilepsy Syndromes of Early Childhood

Mary L. Zupanc

The developing brain is particularly susceptible to seizures. Diffuse central nervous system pathology or injury in early infancy, when the brain is most vulnerable, may lead to catastrophic epilepsies such as Ohtaharas epileptic encephalopathy and early myoclonic epileptic encephalopathy. These epileptic encephalopathies are difficult to treat and have poor prognoses. As the brain undergoes programmed synaptogenesis, apoptosis, and myelination, the epilepsy phenotypes and electroencephalography (EEG) findings change, producing age-dependent epileptic encephalopathies. Specifically, as they grow older, 40% to 60% of infants with infantile spasms and a concomitant hypsarrhythmia on EEG will develop Lennox-Gastaut syndrome with tonic and atonic seizures, associated with a synchronous, generalized 1.5- to 2-Hz spike and slow wave discharges on EEG. In the context of age-dependent epileptic encephalopathies, as an epilepsy syndrome is evolving, it is often difficult to accurately diagnose the specific epilepsy syndrome in a young child who presents with seizures. It is the clinical evolution of the seizure types and the EEG that helps the clinician make an accurate diagnosis. As more is known about the underlying pathophysiology for the various epilepsy syndromes, not only the clinical picture and EEG but also a genetic blood test will be used to accurately diagnose a specific epilepsy syndrome. A case in point would be severe myoclonic epilepsy of infancy (classically known as Dravet syndrome) and severe myoclonic epilepsy of infancy-borderland/ borderline, which are associated with specific mutations in the sodium ion channel gene SCN1A.


Neurology | 2000

Ictal SPECT during autonomic crisis in familial dysautonomia

Felicia B. Axelrod; Mary L. Zupanc; Max J. Hilz; Elissa L. Kramer

Article abstract The authors report results of SPECT cerebral perfusion studies in two patients with familial dysautonomia (FD) during dysautonomic crises and when clinically stable. SPECT imaging studies used 99mTc ethylene cysteine dimer. During dysautonomic crises, regions in the temporoparietal and frontal lobes had increased uptake. Uptake in these areas was less during asymptomatic periods. Episodic asymmetric cerebral perfusion during crises especially affecting the frontal and temporal lobes is suggestive of ictal activity.


Epilepsia | 2008

Long-term management of the ketogenic diet: seizure monitoring, nutrition, and supplementation.

Beth Zupec-Kania; Mary L. Zupanc

The ketogenic diet (KD) is a medical nutrition therapy (MNT) for the treatment of epilepsy. As such, it can affect the outcome of an individuals health and chronic medical condition. The components of MNT which have been established by the American Dietetic Association as core guidelines for nutrition care include a diet history, assessment, diet therapy and a follow‐up plan of care (American Dietetic Assoc 2002). We have utilized these guidelines in designing our approach to KD therapy in our pediatric population. Many of the practices described here have been adopted from our practical experience.


Journal of Neurosurgery | 2011

Corpus callosotomy in multistage epilepsy surgery in the pediatric population

Jessica S. Lin; Sean M. Lew; Charles J. Marcuccilli; Wade M. Mueller; Anne E. Matthews; Jennifer I. Koop; Mary L. Zupanc

OBJECT The object of this study was to evaluate surgical outcome in a select group of patients with medically refractory epilepsy who had undergone corpus callosotomy combined with bilateral subdural electroencephalography (EEG) electrode placement as the initial step in multistage epilepsy surgery. METHODS A retrospective chart review of 18 children (ages 3.5-18 years) with medically refractory symptomatic generalized or localization-related epilepsy was undertaken. A corpus callosotomy with subdural bihemispheric EEG electrode placement was performed as the initial step in multistage epilepsy surgery. All of the patients had tonic and atonic seizures; 6 patients also experienced complex partial seizures. All of the patients had frequent generalized epileptiform discharges as well as multifocal independent epileptiform discharges on surface EEG monitoring. Most of the patients (94%) had either normal (44%) MR imaging studies of the brain or bihemispheric abnormalities (50%). One patient had a suspected unilateral lesion (prominent sylvian fissure). RESULTS Of the 18 patients who underwent corpus callosotomy and placement of subdural strips and grids, 12 progressed to further resection based on localizing data obtained during invasive EEG monitoring. The mean patient age was 10.9 years. The duration of invasive monitoring ranged from 3 to 14 days, and the follow-up ranged from 6 to 70 months (mean 35 months). Six (50%) of the 12 patients who had undergone resection had an excellent outcome (Engel Class I or II). There were no permanent neurological deficits or deaths. CONCLUSIONS The addition of invasive monitoring for patients undergoing corpus callosotomy for medically refractory epilepsy may lead to the localization of surgically amenable seizure foci, targeted resections, and improved seizure outcomes in a select group of patients typically believed to be candidates for palliative surgery alone.


Pediatric Neurology | 2010

Efficacy of Felbamate in the Treatment of Intractable Pediatric Epilepsy

Mary L. Zupanc; Rhonda Roell Werner; Michael S. Schwabe; Sunila E. O'Connor; Charles J. Marcuccilli; Kurt E. Hecox; Maria S. Chico; Kathy A. Eggener

The antiepileptic drug felbamate has demonstrated efficacy against a variety of seizure types in the pediatric population, particularly seizures associated with Lennox-Gastaut syndrome. Postmarketing experience, however, revealed serious idiosyncratic adverse effects not observed during clinical trials, including aplastic anemia and liver failure. As a result, many physicians have been hesitant to prescribe felbamate. This retrospective study evaluated the efficacy of felbamate in a pediatric population with intractable epilepsy. Of 38 patients, 22 had Lennox-Gastaut syndrome (58%); 6 had myoclonic-astatic epilepsy of Doose (16%); 5 had symptomatic generalized epilepsy, not otherwise specified (13%); and 5 had symptomatic localization-related epilepsy (13%). Most patients had multiple seizure types and had been tried on a variety of antiepileptic medications. With felbamate treatment, 6 patients (16%) became seizure free, including 4 of the 6 patients with myoclonic-astatic epilepsy of Doose; 24 patients (63%) had a greater than 50% reduction in seizure frequency. In this population felbamate appeared to be safe, with minimal adverse effects. The study is limited by the small number of patients and by its retrospective nature, but nonetheless adds to the evidence that felbamate is an important antiepileptic drug for medically refractory epilepsy in children and is well tolerated with few adverse effects.


International Review of Neurobiology | 2008

Chapter 5 Epilepsy in Women. Special Considerations for Adolescents

Mary L. Zupanc; Sheryl R. Haut

Adolescence is a time of many changes. It is a time of growing independence, physical and emotional change, accompanied by social insecurity. Girls tend to enter puberty ahead of their male peers, growing and changing physically. Our culture tells adolescents that they are still immature, but their bodies are saying otherwise. The adolescents are also becoming aware of themselves as individuals, separate from their parents, and are presented with the challenges of independent thinking and action. If, in the midst of all of these changes, an adolescent is given the diagnosis of a chronic disease such as epilepsy, there is an additional burden. Often the adolescent must go through a variety of emotions, including shame, denial, anger, and sadness. Our role as medical providers is to provide some perspective to the illness and help guide our adolescent patient through the tumultuous emotions of grieving and acceptance. We must provide a foundation of assistance and emotional support, as well as medical knowledge. With a firm but compassionate hand, we can help them cope with their disorder. In this chapter, Drs. Haut and Zupanc explore some of the unique considerations in adolescent women with epilepsy. The first part of the chapter deals with the epidemiologic diagnosis of epilepsy in adolescence, the effect of epilepsy on reproductive health, hormonal influences on epilepsy (including catamenial seizures), and the effects of antiepileptic drugs (AEDs) on hormones, contraception, and bone health. In the second part of the chapter, we deal with the very real psychosocial issues and comorbidities of epilepsy, including quality of life, school performance, depression, migraine headaches, social stigma, and lifestyle changes. In the final section, the authors suggest strategies for clinical patient management.

Collaboration


Dive into the Mary L. Zupanc's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Rhonda Roell Werner

Children's Hospital of Wisconsin

View shared research outputs
Top Co-Authors

Avatar

Sunila E. O'Connor

Children's Hospital of Wisconsin

View shared research outputs
Top Co-Authors

Avatar

Beth Zupec-Kania

Children's Hospital of Wisconsin

View shared research outputs
Top Co-Authors

Avatar

Kathy A. Eggener

Children's Hospital of Wisconsin

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sean M. Lew

Medical College of Wisconsin

View shared research outputs
Top Co-Authors

Avatar

Sheryl R. Haut

Albert Einstein College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Wade M. Mueller

Medical College of Wisconsin

View shared research outputs
Researchain Logo
Decentralizing Knowledge